StockNews.AI

*CORRECTION*INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

StockNews.AI • 7 hours

INO
High Materiality8/10

Information

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Inovio Pharmaceuticals is under investigation for possible securities fraud, with Pomerantz LLP leading the charge. The company's Biologics License Application for INO-3107 received FDA acceptance but failed to qualify for accelerated approval, leading to a significant stock drop of over 24%. This scrutiny may negatively impact investor sentiment while Inovio seeks alternatives.

Sentiment Rationale

Historical examples such as Theranos show that investigations can lead to prolonged stock declines. INO's failure to secure accelerated approval adds to its precarious situation.

Trading Thesis

Sell INO as legal issues and regulatory setbacks could drive stock lower in the near term.

Market-Moving

  • Ongoing investigation by Pomerantz LLP could lead to further legal liabilities for INO.
  • The lack of accelerated approval may delay INO-3107's market entry.
  • Investor sentiment could weaken on potential class action involvement.
  • Previous stock drop signals potential volatility in the short-term outlook.

Key Facts

  • Pomerantz LLP investigates Inovio for potential securities fraud.
  • Inovio's BLA for INO-3107 accepted but lacks accelerated approval eligibility.
  • Company will not pursue standard review approval timeline.
  • Stock fell over 24% following FDA's announcement about BLA.
  • Investors are being solicited to join the possible class action.

Companies Mentioned

  • Inovio Pharmaceuticals, Inc. (INO): Facing investigation and stock volatility may impact investor confidence.
  • Pomerantz LLP (N/A): Leading class-action investigation that may bring legal consequences for INO.

Corporate Developments

This analysis fits the 'Corporate Developments' category as it revolves around legal actions and regulatory hurdles impacting the company's operations and investor sentiment.

Investor Alert: Pomerantz Law Firm Investigates Inovio Pharmaceuticals, Inc. (INO)

On January 20, 2026, Pomerantz LLP announced an investigation concerning potential claims on behalf of investors in Inovio Pharmaceuticals, Inc. (NASDAQ: INO). This inquiry aims to determine whether Inovio and certain officers or directors may have engaged in securities fraud or other unlawful business practices. Investors with information relevant to this matter are encouraged to contact Danielle Peyton via email at newaction@pomlaw.com or by phone at 646-581-9980, ext. 7980.

FDA’s Review of Inovio’s BLA for INO-3107

On December 29, 2025, the U.S. Food and Drug Administration (FDA) accepted Inovio's Biologics License Application (BLA) for INO-3107, a treatment aimed at recurrent respiratory papillomatosis. However, the FDA noted that the application did not provide adequate information to support eligibility for accelerated approval, a pathway Inovio originally aimed to pursue.

Market Reaction and Stock Performance

The announcement had a significant impact on Inovio’s stock price, which dropped by $0.56 per share, representing a 24.45% decline, ultimately closing at $1.73 per share on the same day. This steep decline raises concerns among investors regarding the company’s future prospects and their investments in INO.

Pomerantz LLP’s Role in Protecting Investors

Pomerantz LLP, a renowned law firm with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has a long-standing reputation in corporate, securities, and antitrust litigation. Founded by the late Abraham L. Pomerantz, the firm has been at the forefront of securities class actions for over 85 years, advocating for victims of securities fraud and corporate misconduct.

With a history of recovering multimillion-dollar damages for its clients, Pomerantz is committed to ensuring that investors impacted by possible infractions gain the support they need.

Contact Information for Investors

  • Contact: Danielle Peyton
  • Firm: Pomerantz LLP
  • Email: dpeyton@pomlaw.com
  • Phone: 646-581-9980 ext. 7980

Related News